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Endocrine changes supervening after parturition and menopause participate in the control of sebum production and hair growth
modulation. The ensuing conditions include some peculiar aspects of hair loss (effluvium), alopecia, and facial hirsutism.The hair
cycling is of major clinical relevance because most hair growth disorders result from disturbances in this chronobiological feature.
Of note, any correlation between a biologic abnormality and hair cycling disturbance does not prove a relationship of causality.The
proportion of postmenopausal women is rising in the overall population.Therefore, the prevalence of these hair follicle disturbances
is globally on the rise. Current therapies aim at correcting the underlying hormonal imbalances, and at improving the overall
cosmetic appearance. However, in absence of pathogenic diagnosis and causality criteria, chances are low that a treatment given
by the whims of fate will adequately control hair effluvium. The risk and frequency of therapeutic inertia are further increased.
When the hair loss is not controlled and/or compensated by growth of new hairs, several clinical aspects of alopecia inexorably
develop. Currently, there is little evidence supporting any specific treatment for these endocrine hair disorders in post-partum
and postmenopausal women. Current hair treatment strategies are symptomatic and nonspecific so current researchers aim at
developing new, targeted methods.
1. Introduction
The hair follicle represents a complex miniorgan consisting
of different cell populations characterized by their distinct
locations, functions, and molecular component expressions.
It represents a uniquely dynamic system undergoing con-
tinuous growth cycles throughout life [1, 2]. This miniorgan
normally regenerates itself 8 to 10 times during the human
lifespan [3]. The cyclic hair follicle transformation process
arises under the control of an oscillator system called “the
hair cycle clock.” It occurs simultaneously with changes in the
sebaceous gland, perifollicular dermis, and subcutis [3, 4].1
2 A synchronized hair cycle prevails in most mammalspreparing hair coat for seasonal environmental changes.
In humans, hair growth is not a continuous process, but
it follows a successive asynchronous rhythm leading to a
periodic regeneration of hair follicles. The reason for this
unsynchronized process in humans is unclear [5]. The hair
cycle is controlled by various hormones and local growth
factors probably produced both inside and nearby the hair
bulb and follicular papilla [6]. In addition, minute envi-
ronmental changes potentially affect the hair biology. Hair
growth disorders are attributed, at large, to alterations in the
normal dynamics of the hair cycle [1, 7]. The total density of
hair shafts is then altered [1, 8].
Some of the clinical consequences of disturbed hair biol-
ogy are gender dependent. A series of clinical presentations
are quite specific at some periods of women’s life. For each of
these conditions, the pathomechanism appears quite distinct,
allowing for expecting some future progress in their manage-
ment.This review aims at raising awareness in the problems of
hair disorders in postpregnant and menopausal women and
discussing some assessment and treatment options pertinent
to this group of women.
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2. Basic Aspects of Hair Cycle Chronobiology
Clearly, there is awide range of hair complaints inwomen, but
it remains quite impossible to find relevant epidemiological
data in the literature. Hair growth involves a unique process
of cyclic regeneration from follicles undergoing phases of
growth and rest [1, 3, 5, 7, 8]. The succession of the anagen,
catagen, and telogen phases follows a recurrent period closely
controlled by chronobiological synchronizers. The duration
of the hair cycle is influenced by age, pathology, and a wide
variety of physiological factors.The anagen phase duration of
any individual hair ranges from about three to six years. This
hair growth phase is characterized by intense cell renewal
followed by terminalmaturation. It involves epithelial growth
of the hair bulb deep into the dermis with generation of a hair
shaft (Figure 1). At completion of this growth phase, the hair
bulb follows a rapid involution of the hair follicle during the
catagen phase. The hair follicle retracts up to the mid part of
the hair follicle and proceeds to the quiescent telogen phase.
About 15 to 20% of scalp hairs are usually in telogen. After
three months in average, a new hair bulb is expected at the
base of the same follicle as the new successor anagen hair
shaft. As it grows down, the old telogen hair is expelled. In
such a process, each shed hair is ideally replaced by a new one.
Although the actual mechanisms involved in hair shedding
are not fully identified the process leading to the final hair
shedding is possibly driven by the conjunction of activities of
proteases and protease inhibitors [9–11]. At completion of the
telogen phase, the club hair shaft remains loosely anchored to
the follicular outer root sheath. The end of the telogen phase
at the time of hair shedding corresponds to teloptosis/exogen
phase [12, 13]. The hair falls spontaneously or is removed by
gentle combing and washing. It is believed to be pushed out
when the new anagen hair emerges. However, the process of
hair shedding possibly occurs in humans regardless of the
other hair cycle phases [1, 5].
The chronobiology control system driving the cyclic
process in the hair follicle remains putative. Controls of the
onset and duration of any hair cycle phase are complex. They
possibly involve a series of up- and downregulated synchro-
nizers. The whole process sustains hair growth moving from
one growth stage in the hair cycle to the next [12].
During hair cycling, a series of cell types and structures
are involved. They include endothelial cells, lymphocytes,
basement membranes, proteoglycans, and the abutted con-
stitutive cells of the epidermis, dermis, and hypodermis
[14]. They possibly influence the cycle. Whether some of
these changes represent causative or concomitant features
is not established. The most obvious driving force in the
hair cycle appears issued from both the follicular papilla
and the perifollicular matrix. Indeed, prominent structural
changes occur in these structures during the hair cycle. The
follicular papilla is large in established anagen. It becomes
smaller andmore compact in telogen.The size of the follicular
papilla dictates the size and shape of the follicle [14–16] which
are particularly dictated by the body location. The variable
papilla dimensions during the hair cycle are reflected in
the extracellular matrix, remodelling with accumulation of
proteoglycans including versican [17].The vascular structures
Figure 1: Growing hair in anagen phase with numerous cells in S
phase of proliferation in the hair bulb and a few others in the dermal
papilla. Tritiated thymidine autoradiography.
become more prominent during the growth phase. Factors
from the papillary mesenchymal cells probably act on the
follicular epithelium.At initiation of the anagenphase, factors
from the papilla influence stem cells of the hair follicle that are
receptive to inductive signals [18].
3. Coordination between Successive Hair
Cycles
In subjects with reduced hair density, most follicles contain
only a single hair, and some others appear empty [19].
By contrast, in hair fullness conditions, follicular openings
commonly contain a couple of hairs. This aspect is possibly
due to several hair follicles sharing in common a single
infundibulum. Delayed teloptosis further influences such
pattern [13]. Teloptosis can occur concurrently as the hair
follicle initiates the next early anagen stage or has already
been in anagen for some time.
By contrast, in some conditions the telogen hair is lost
before the next anagen hair becomes visible. During the
latency period, the hair follicle appears empty at the clinical
inspection [20–22]. The lag time before the extrusion of
the next generation of hair corresponds to the hair eclipse
phenomenon [22]. This physiological feature is more or
less prolonged, reaching 4 to 7 months in average [20,
23]. It obviously influences the hair density of the scalp.
The hair eclipse phenomenon likely depends on a series of
distinct synchronizers. It results from some dysregulations
in the hair cycling involving early teloptosis, delayed anagen
initiation, or stunted hair growth at any step during the
anagen stage. As such, the hair eclipse phenomenon presents
as an erratic process occurring in a series of physiopatho-
logical conditions affecting hair follicles singly or in focal
to generalized patterns. It is more frequent following syn-
chronized teloptosis occurring in telogen effluvium such as
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a postpartum alopecia. Local synchronizers including growth
factors and othermediators are eventually lacking or involved
in the hair eclipse phenomenon. Their identification and
characterization possibly drive new corrective and preventive
applications.
The underlying causative mechanisms of generalized
hair eclipse phenomenon are probably diverse. They remain
unsettled. Two typical examples are given by the arrest of
hair growth during the midanagen phase in alopecia areata
and in the transient baldness occurring in some newborns
or after chemotherapy. The chronic telogen effluvium [21]
is similarly followed by the hair eclipse phenomenon. The
diversity of causes and mechanisms involved in the hair
eclipse phenomenon is remarkable [5, 20].
4. Postpartum Hair Loss
Most women suffer from telogen effluvium during post-
partum [1, 24, 25]. Indeed, during pregnancy, the telopto-
sis/exogen phase is delayed and the number of shedding
hairs is reduced, inducing increased hair fullness. After
delivery, the hair cycles become synchronized on the scalp
of these women ending in a synchronous telogen-teloptosis
process [26]. At that time, hair loss appears abundant but
only represents the elimination of the additional hairs that
had been maintained in anagen phase and had not been
lost during gestation. In the second and third quarters of
pregnancy only about 10% of hairs are in telogen.
Postpartum hair loss is commonplace and considered as
a minor nuisance by women who have previously passed
through it. However, it possibly represents a panic condition
for thesewho experience it for the first time.The sameprocess
operates following severe febrile conditions. During the first
weeks of postpartum, hairs enter telogen in a synchronous
wave to reach about 30% in average after nine weeks. This
explains the clinical observation that postpartum hair loss is
experienced two to four months after childbirth. It usually
continues for 6 to 24weeks but rarely persists up to 15months.
Postpartum hair loss from the scalp is diffuse but is
accentuated along the anterior hair line. Virtually the whole
hair is replaced after several weeks unless some other process
unmasks female pattern alopecia.
5. Hair Follicles during Climacteric
The average age at natural menopause is about 49–51 years.
The hair follicles are often affected at that period of life.
Indeed, hair represents a specific receptor structure express-
ing declines related to fluctuations in circulating levels of sex
steroids. The two major changes in hair distribution seen
at menopause are female pattern alopecia (FPA) and facial
hirsutism. Both conditions are often concomitant and seem
to be more pronounced with increasing postmenopausal
years. Tibolone, as an alternative to hormone replacement
therapy (HRT), has been reported to increase the severity
of diffuse alopecia and possibly induce facial hypertrichosis
[27]. Frontal fibrosing alopecia (FFA) is a distinct condition
probably accentuated by menopause, although it is not
controlled by HRT.
6. Climacteric Hair Loss
Most women in developed societies expect to spend a third
or more of their lives after menopause. Aging associated with
climacteric hormonal changes commonly affects some hair
characteristics and is responsible for decreased hair coverage
in middle-aged women [28]. The most common form of
progressive alopecia in elderly women is FPA, which often
worsens during the perimenopause, particularly if the con-
dition was previously present [29, 30]. The decreased anagen
phase duration and regression of scalp hair to finer vellus hair
are particularly caused by androgens.They commonly lead to
climacteric alopecia [23]. Of note, some women presenting
with alopecia do not show any increase in androgen circulat-
ing levels, suggesting that their androgen skin receptors are
abundant or that other androgen-independent mechanisms
are involved [29]. FPA particularly affects hair follicles from
the parietal and frontosagittal areas causing bitemporal hair
thinning but leaving an intact frontal hairline [29, 31]. In this
condition, both the scalp stratum corneum and the hair shafts
show a decreased capacitance level indicating an impaired
moisturization [32, 33].
Postmenopausal FFA is a distinct cicatricial alopecia [34–
36]. It corresponds to a progressive condition responsible for
the destruction of the upper portion of the hair follicle by
a lymphoid cell infiltrate. This process induces a distinctive
pattern of hair rarefaction corresponding to a symmetrical
regression of the frontal and temporal hairline, combined
with partial to complete loss of the eyebrows [34–36]. The
hair loss onset is particularly difficult to identify as patients
present relatively late during the disease progression. Hence,
FFA is often stable and this impacts the treatment efficacy
[25, 36]. In addition, it remains unsettled how climacteric
changes cause this selective targeting of the frontotemporal
scalp. However, some benefit has been reported in a few
patients following androgen-dependent therapy [24, 26, 35].
7. Pregnancy and Climacteric Facial Hirsutism
Increased hair growth during pregnancy is a rare condition
associated with signs of virilization such as deep voice,
acne, and clitoral enlargement. In some of these patients an
arrhenoblastomawas disclosed, and in other women bilateral
ovarian enlargement results from lutein cell hyperplasia.
Virilization possibly disappears during postpartum in asso-
ciation with a spontaneous decrease in the ovarian size.
Body hair in women usually tends to rise until
menopause. Later on, it begins to decrease. By contrast,
facial hair tends to increase even in the elderly. The
prevalence of hirsutism in postmenopausal women has not
been fully documented [37]. About 50% of women report
excessive facial hair growth after menopause [38]. This
feature suggests that both the clinical and social importance
of this problem is underestimated in many instances.
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In general, hirsutism is due to increased androgen pro-
duction or to greater sensitivity of the hair follicles to these
hormones [39]. Androgens are responsible for increasing
the hair follicle size, hair shaft diameter, duration of the
anagen phase of terminal hairs, and sebum production. All
these aspects are typically present in hirsutism [40]. The
vast majority of hirsute women suffer from a benign causal
disorder.The twomain causes are polycystic ovary syndrome
(PCOS) and idiopathic hirsutism with circulating androgen
levels within normal range [41–45]. Although PCOS and
the associated hormone imbalances were observed after
menopause, the level of hyperandrogenism appearedmodest.
More serious but rare causes of hirsutism include the
congenital adrenal hyperplasia and Cushing’s syndrome,
as well as some benign and malignant androgen-secreting
ovarian and adrenal tumours [38, 46, 47]. Hyperandrogenism
caused by adrenal ganglioneuroma [48] and ovarian-related
hyperandrogenism associated with hirsutism including those
related to ovarian hyperthecosis [49–51] and ovarian neo-
plasms [52] have been reported. Severe virilisation in post-
menopausal women with nonmalignant origin is rare. Occa-
sionally, postmenopausal hirsutism follows androgen therapy
including testosterone [53] and androgen-estrogen hormone
therapy [54].
8. Conclusion
By stressing the uniqueness of some hair disorders in women,
those diseases and their treatment should comemore sharply
into focus. The ultimate goal is to better prevent, diagnose,
and treat the hair disorders inwomen.The causes of hirsutism
and hair loss as well as the management of these condi-
tions are occasionally different in postmenopausal women
compared with women of younger reproductive age [55].
Some postmenopausal women probably deserve special care
and attention when entering the new phase in their lives
supported by complex physiological changes. Chronobiology
governing the hair cycle is a fascinating and complex process.
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